In future corona vaccine orders, the European Commission hopes to focus mainly on vaccines using so-called mRNA technology, such as Pfizer/BioNTech and Moderna. President Ursula von der Lein said.
This intent does not mean that pharmaceutical companies that do not use the technology will not have the opportunity to make new purchases. Von der Leyen also stated that the committee prefers vaccines made in Europe.
The European Commission hopes to order 1.8 billion doses of vaccine in a new round of vaccination from 2021 to 2023. German pharmaceutical company Curevac is also studying vaccines made using mRNA technology. The vaccine is expected to be available next summer.
In vaccines using mRNA technology, the human body will produce viral proteins based on genetic material, and the human body will produce antibodies against the proteins.
AstraZeneca and Janssen
Neither AstraZeneca Corona Vaccine nor Johnson & Johnson’s Jansen Vaccine uses mRNA technology. It is these vaccines that are temporarily not used in many countries because they are related to blood clotting in the brain and lack of platelets.
According to the European Medicines Agency EMA, the benefits of the AstraZeneca vaccine outweigh this very rare side effect. opportunity It may be less than one in 100,000.
EMA’s investigation into blood clotting and thrombocytopenia while using the Janssen vaccine is still ongoing. The results are expected next week. According to EMA, the current benefits of this vaccine also outweigh the potential risks.